Carcinoembryonic Antigen (CEA)
Use
This assay is intended for the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma.1 The Elecsys CEA assay is further indicated for serial measurement of CEA to aid in the management of cancer patients. The main indication for CEA determinations is the follow-up and therapy-management of colorectal carcinoma.
Special Instructions
Values obtained with different assay methodologies should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please order the serial monitoring test (480095). Biotin interference can occur; patients should stop biotin consumption at least 72 hours prior to sample collection.
Limitations
CEA determinations are not recommended for cancer screening in the general population. Serum CEA values can vary based on the test procedure and may result in erroneous medical interpretations if different methods are used for comparisons. Erroneous findings may occur in the presence of high titers of antibody to streptavidin and ruthenium. Results should always be considered alongside patient history and other clinical findings.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 2039-6
- 2039-6
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.7 mL
Container
Gel-barrier tube (preferred) or red-top tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Storage Instructions
Room temperature
Causes for Rejection
Citrate plasma specimen; improper labeling
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant